Roche to acquire liver drug developer 89bio for up to $3.5 billion

Roche’s Metabolic Drug Strategy Extends to the Liver Disease MASH With $2.4B 89bio Acquisition

Roche is buying 89bio to get pegozafermin, a drug currently in two Phase 3 studies for the fatty liver disease MASH. Beyond the $2.4 billion payable when the deal closes, another $1.1 billion in contingent value right payments is tied to the achievement of commercial milestones for the projected blockbuster seller. The post Roche’s Metabolic Drug Strategy Extends to the Liver Disease MASH With $2.4B 89bio Acquisition appeared first on MedCity Ne…

Swiss pharma firm Roche to acquire US-based biotech firm 89bio for $3.5B

Deal to foster Roche's activities to build 'robust,' differentiated pipeline that targets additional causes of metabolic disease - Anadolu Ajansı

Roche to acquire liver drug developer 89bio for up to $3.5 billion

Roche has agreed to buy U.S. biotech firm 89bio for up to $3.5 billion, joining a race to offer new liver disease treatments that complement an intense push in the area of weight-loss drugs.

Roche dives into MASH with $2.4B deal for 89bio

Roche’s CEO claimed 89bio’s drug, which is in late-stage testing, has the potential to show “best-in-disease efficacy” for many people with the condition.

Roche poised to buy MASH drug developer 89bio for $3.5bn

Roche has dipped its toe in the M&A water with an agreement to buy US biotech 89bio and its phase 3 candidate pegozafermin for MASH.

Roche to buy 89bio for up to $3.5b

The company, which was founded in Israel, has a drug for treatment of fatty liver in phase III trials, which was initially an asset of Teva.